ABUS - アルブ―タス・バイオファ―マ （Arbutus Biopharma Corporation）

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

Arbutus Biopharma (ABUS) announces its 2022 corporate objectives and provided a financial update

Arbutus Biopharma Corporation (NASDAQ:ABUS) with the stream of 0.00% also noticed, India Banco Santander, S.A. (NYSE:SAN) encountered a rapid change of 2.84% in the last hour of Thursdays trading session. The post Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) appeared first on Stocks Equity .

Arbutus Biopharma Co. (NASDAQ:ABUS) traded down 2.9% during trading on Thursday . The company traded as low as $4.00 and last traded at $4.04. 60,266 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 25,955,150 shares. The stock had previously closed at $4.16. A number of equities research []

The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details,

Arbutus Biopharma Corporation (NASDAQ:ABUS) with the stream of 0.00% also noticed, India Banco Santander, S.A. (NYSE:SAN) encountered a rapid change of 2.84% in the last hour of Thursdays trading session. The post Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) appeared first on Stocks Equity .

Arbutus Biopharma Co. (NASDAQ:ABUS) traded down 2.9% during trading on Thursday . The company traded as low as $4.00 and last traded at $4.04. 60,266 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 25,955,150 shares. The stock had previously closed at $4.16. A number of equities research []

The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details,

Equities analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to announce earnings of ($0.18) per share for the current quarter, Zacks reports. Two analysts have made estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of ($0.23) in []

Equities research analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to report sales of $3.39 million for the current quarter, Zacks reports. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest sales estimate coming in at $3.47 million and the lowest estimate coming in at $3.30 million. Arbutus Biopharma posted sales of $2.39 million []

Arbutus Biopharma Co. (NASDAQ:ABUS) shares saw strong trading volume on Wednesday . 814,409 shares changed hands during trading, a decline of 61% from the previous sessions volume of 2,086,054 shares.The stock last traded at $4.40 and had previously closed at $3.20. A number of equities analysts have weighed in on the stock. HC Wainwright reduced []

Nuveen Asset Management LLC bought a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) in the 2nd quarter, Holdings Channel reports. The fund bought 226,012 shares of the biopharmaceutical companys stock, valued at approximately $685,000. Several other institutional investors have also made changes to their positions in ABUS. Northern Trust Corp grew its stake []

Northern Trust Corp raised its position in Arbutus Biopharma Co. (NASDAQ:ABUS) by 441.9% in the second quarter, HoldingsChannel reports. The fund owned 719,159 shares of the biopharmaceutical companys stock after purchasing an additional 586,456 shares during the quarter. Northern Trust Corps holdings in Arbutus Biopharma were worth $2,179,000 as of its most recent SEC filing. []

During the last session, Arbutus Biopharma Corporation (NASDAQ:ABUS)s traded shares were 0.72 million, with the beta value of the company hitting 2.58. At the end of the trading day, the stocks price was $3.19, reflecting an intraday gain of 2.24% or $0.07. The 52-week high for the ABUS share is $5.87, that puts it down Arbutus Biopharma Corporation (NASDAQ: ABUS) Stock Dropped -21.62% Over A Month Are There Any Chances Of Growth? Read More »

Brokerages expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post ($0.18) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of []